Last reviewed · How we verify
DP
DP is a medication used to treat certain types of infections caused by bacteria.
DP is a medication used to treat certain types of infections caused by bacteria. Used for Treatment of infections caused by susceptible bacteria, including pneumonia, skin and soft tissue infections, and urinary tract infections.
At a glance
| Generic name | DP |
|---|---|
| Also known as | DuoCotecxin, Holley Pharm |
| Sponsor | Medecins Sans Frontieres, Netherlands |
| Drug class | Betalactam antibiotic |
| Target | transpeptidase |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | FDA-approved |
Mechanism of action
DP works by inhibiting the synthesis of bacterial cell walls, ultimately leading to the death of the bacteria. This is achieved through the inhibition of the enzyme transpeptidase, which is essential for the cross-linking of peptidoglycan in the bacterial cell wall.
Approved indications
- Treatment of infections caused by susceptible bacteria, including pneumonia, skin and soft tissue infections, and urinary tract infections
Common side effects
- Allergic reactions
- Diarrhea
- Nausea and vomiting
- Abdominal pain
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DP CI brief — competitive landscape report
- DP updates RSS · CI watch RSS
- Medecins Sans Frontieres, Netherlands portfolio CI